Executive Summary Thai Pulmonary Hypertension
Guidelines 2020
Kritvikrom Durongpisitkul MD¹, Suree Sompradeekul MD¹, Ratanavadee Nanagara MD², Decho Jakrapanichakul MD¹,
Suthep Wanitkun MD³, Alisa Limsuwan MD³, Nattapong Jaimchariyatam MD⁴, Prasert Sawasdiwipachi MD¹,
Smonporn Boonyaratavej MD⁴, Pornthep Lertsapcharoen MD⁴, Burabha Pussadhamma MD², Prapaporn Pornsuriyasak MD³,
Worawit Louthrenoo MD⁵, Emvalee Arromdee MD¹, Paweena Chungsomprasong MD¹, Chodchanok Vijarnsorn MD¹,
Srisakul Chirakarnjanakorn MD¹, Arintaya Phrommintikul MD⁵, Apichart Kanit
Affiliation :
¹ Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand ² Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand ³ Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand ⁴ Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand ⁵ Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand ⁶ Faculty of Medicine, Thammasat University, Pathumthani, Thailand ⁷ Central Chest Institute of Thailand, Nonthaburi, Thailand ⁸ Phramongkutklao College of Medicine, Bangkok, Thailand
In 2011, the Heart Association of Thailand (HAT) approved the first Thai guideline for the diagnosis and management of patients with pulmonary hypertension
(PH). Since then, significant changes have occurred in the diagnosis and management of patients with PH, such as risk assessment and new strategies for
combination therapies based on the 2015 European Society of Cardiology (ESC)/European Respiratory Society (ERS) pulmonary hypertension guidelines. The
most recently updated definition of PH was from the Sixth World Symposium on Pulmonary Hypertension in 2018. Hence, HAT has revised the Thai guidelines
for the diagnosis and management of patients with PH, which was approved by the Royal College of Physicians of Thailand in 2019. These guidelines are
intended for use by 1) general practitioners for preliminary diagnoses and referral to a PH referral center and 2) specialist physicians such as cardiologists and
pulmonologists, to collaborate in the caring process and diagnosis and management, including the use of Pulmonary artery hypertension (PAH)-specific drugs.
The guidelines were written in Thai language to be easily understood and approved by HAT and the Royal College of Physicians of Thailand in 2019. The current executive summary is aimed to highlight important details of the 2020 Thai Pulmonary Hypertension Guidelines for a broader distribution. This updated version of the executive summary of the guidelines is aimed to achieve three objectives, 1) early diagnosis by using the algorithm, including pathophysiology into one of five PH groups, 2) risk assessment for PAH patients into low, intermediate, or high risk, and 3) sequential combination therapy as indicated by the risk assessment for PAH-specific drugs to maintain PAH patients within the low-risk group as much as possible to improve their long-term survival.
Received 7 October 2020 | Revised 27 December 2020 | Accepted 6 January 2021
doi.org/10.35755/jmedassocthai.2021.04.11939
Keywords :
Guideline, Pulmonary hypertension, Diagnosis, Management
All Articles
Download